MCID: PRD017
MIFTS: 24

Periodic Paralyses malady

Category: Genetic diseases (common)

Aliases & Classifications for Periodic Paralyses

About this section

Aliases & Descriptions for Periodic Paralyses:

Name: Periodic Paralyses 46

Classifications:



Summaries for Periodic Paralyses

About this section
NINDS:46 Familial periodic paralyses are a group of inherited neurological disorders caused by mutations in genes that regulate sodium and calcium channels in nerve cells. They are characterized by episodes in which the affected muscles become slack, weak, and unable to contract. Between attacks, the affected muscles usually work as normal.

MalaCards based summary: Periodic Paralyses is related to familial periodic paralyses and myocardial infarction. An important gene associated with Periodic Paralyses is KCNJ2 (Potassium Voltage-Gated Channel Subfamily J Member 2), and among its related pathways are Antiarrhythmic Pathway, Pharmacodynamics and Renin secretion. Affiliated tissues include t cells, thyroid and breast, and related mouse phenotypes are respiratory system and digestive/alimentary.

Related Diseases for Periodic Paralyses

About this section

Diseases in the Periodic Paralyses family:

Familial Periodic Paralyses

Diseases related to Periodic Paralyses via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
idRelated DiseaseScoreTop Affiliating Genes
1familial periodic paralyses12.7
2myocardial infarction10.4
3pheochromocytoma10.2
4xeroderma pigmentosum, group b10.2
5breast cancer10.2
6renal cell carcinoma10.2
7wiskott-aldrich syndrome10.2
8angina pectoris10.2
9acute myocardial infarction10.2
10chronic granulomatous disease10.2
11paraganglioma10.2
12tetanus10.2
13cholestasis10.2
14sclerosing cholangitis10.2
15pleuropneumonia10.2
16sporotrichosis10.2
17prostatitis10.2
18intrahepatic cholestasis10.2
19acromegaly10.2
20myofibroma10.2
21acute stress disorder10.2
22amyloidosis10.2
23cholangitis10.2
24chronic graft versus host disease10.2
25endotheliitis10.2
26myasthenic syndrome, congenital, 1610.0KCNE3, SCN4A
27polyhydramnios, megalencephaly, and symptomatic epilepsy10.0KCNE3, SCN4A
28hypokalemic periodic paralysis, type 210.0KCNE3, SCN4A
29myotonia congenita, atypical, acetazolamide-responsive10.0KCNE3, SCN4A
30hypertelorism, preauricular sinus, punctal pits, and deafness10.0KCNE3, SCN4A
31hypertrichosis terminalis, generalized, with or without gingival hyperplasia9.9KCNJ2, SCN4A
32neuropathy, hereditary sensory, type if9.9CACNA1S, KCNE3
33cystoisosporiasis9.8CACNA1S, SCN4A
34mcleod neuroacanthocytosis syndrome9.7CACNA1S, SCN4A
35tibia absent polydactyly arachnoid cyst9.7CACNA1S, KCNJ2
36hypokalemia9.7CACNA1S, SCN4A
37atrioventricular septal defect9.7KCNE3, KCNJ2
38tonsillar fossa cancer9.6CACNA1S, SCN4A
39orofaciodigital syndrome9.6CACNA1S, SCN4A
40pyoderma gangrenosum9.6CACNA1S, SCN4A
41persistent vegetative state9.2CACNA1S, KCNE3, KCNJ2, SCN4A
42paramyotonia congenita9.2CACNA1S, KCNE3, KCNJ2, SCN4A
43prostate lymphoma9.2CACNA1S, KCNE3, KCNJ2, SCN4A
44hypokalemic periodic paralysis, type 19.2CACNA1S, KCNE3, KCNJ2, SCN4A

Graphical network of the top 20 diseases related to Periodic Paralyses:



Diseases related to periodic paralyses

Symptoms for Periodic Paralyses

About this section

Drugs & Therapeutics for Periodic Paralyses

About this section

Drugs for Periodic Paralyses (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DichlorphenamideapprovedPhase 32120-97-83038
Synonyms:
1,3-Disulfamoyl-4,5-dichlorobenzene
1,3-Disulfamyl-4,5-dichlorobenzene
1,3-disulfamoyl-4,5-dichlorobenzene
120-97-8
2pou
3,4-Dichloro-5-sulfamylbenzenesulfonamide
4,5-DICHLOROBENZENE-1,3-disulfonamide
4,5-Dichloro-1,3-benzenedisulfonamide
4,5-Dichloro-1,3-disulfamoylbenzene
4,5-Dichloro-benzene-1,3-disulfonic acid diamide
4,5-Dichloro-m-benzenedisulfonamide
4,5-Dicholorobenzene-1,3-disulfonamide
4,5-dichloro-1,3-disulfamoylbenzene
4,5-dichloro-m-benzenedisulfonamide
4,5-dichlorobenzene-1,3-disulfonamide
AC1L1F18
Antidrasi
BPBio1_000745
BRD-K71499074-001-03-8
BRN 2703329
BSPBio_000677
Barastonin
C07459
C6H6Cl2N2O4S2
CAS-120-97-8
CB 8000
CHEBI:101085
CHEMBL17
CID3038
D004005
D00518
DB01144
DB07948
Daranide
Daranide (TN)
Dasanide
Dichlofenamide
Dichlorophenamide
Dichlorophenamide (DCP)
 
Dichlorphenamid
Dichlorphenamide
Dichlorphenamide (USP)
Dichlorphenamide [BAN]
Diclofenamid
Diclofenamida
Diclofenamida [INN-Spanish]
Diclofenamide
Diclofenamide (JP15/INN)
Diclofenamidum
Diclofenamidum [INN-Latin]
EINECS 204-440-6
FT-0084528
Glafco
Glajust
Glaucol
Glauconide
Glaumid
HMS1570B19
HSDB 3267
I7A
LS-30043
Llorens Brand of Dichlorphenamide
MLS002154010
Merck Brand of Dichlorphenamide
MolPort-004-285-635
NCGC00016371-01
NCGC00016371-02
Oratrol
Prestwick0_000809
Prestwick1_000809
Prestwick2_000809
Prestwick3_000809
Prestwick_1071
S2177_Selleck
SBB058142
SMR001233338
SPBio_002598
UNII-VVJ6673MHY
ZINC00896918
dichlorphenamide
2
Lamotrigineapproved, investigationalPhase 317984057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
3Excitatory Amino AcidsPhase 31109
4Carbonic Anhydrase InhibitorsPhase 3153
5Sodium Channel BlockersPhase 31180
6Excitatory Amino Acid AntagonistsPhase 31095
7Neurotransmitter AgentsPhase 314795
8AnticonvulsantsPhase 32249
9Diuretics, Potassium SparingPhase 31445
10calcium channel blockersPhase 31743
11Calcium, DietaryPhase 34678
12HopsNutraceuticalPhase 331
13
BumetanideapprovedPhase 21528395-03-12471
Synonyms:
28395-03-1
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid
3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
AB00052253
AC-15228
AC1L1DR5
Aquazone
AstraZeneca Brand of Bumetanide
Atlantis Brand of Bumetanide
B 3023
B3023_SIGMA
BPBio1_000168
BRD-K38197229-001-06-7
BRN 2185351
BSPBio_000152
BSPBio_001508
BSPBio_003061
Bio1_000421
Bio1_000910
Bio1_001399
Bio2_000228
Bio2_000708
Bumedyl
Bumetanida
Bumetanida [INN-Spanish]
Bumetanide
Bumetanide (JP15/USP)
Bumetanide (JP15/USP/INN)
Bumetanide AstraZeneca Brand
Bumetanide Atlantis Brand
Bumetanide Farmacusi Brand
Bumetanide Grossmann Brand
Bumetanide Leo Brand
Bumetanide Roche Brand
Bumetanide Senosiain Brand
Bumetanide [USAN:BAN:INN:JAN]
Bumetanidum
Bumetanidum [INN-Latin]
Bumethanide
Bumex
Bumex (TN)
Bumex, Bumetanide
Burine
Burinex
Butinat
C17H20N2O5S
CAS-28395-03-1
CHEBI:3213
CHEMBL1072
CID2471
CPD000058418
Cambiex
D002034
D00247
DB00887
Diurama
DivK1c_000034
Drenural
EINECS 249-004-6
EU-0100162
Farmacusi Brand of Bumetanide
Fontego
Fordiuran
Grossmann Brand of Bumetanide
HMS1361L10
HMS1568H14
HMS1791L10
 
HMS1921B20
HMS1989L10
HMS2089P13
HMS2092N03
HMS500B16
I06-2277
IDI1_000034
IDI1_033978
KBio1_000034
KBio2_000228
KBio2_001797
KBio2_002796
KBio2_004365
KBio2_005364
KBio2_006933
KBio3_000455
KBio3_000456
KBio3_002561
KBioGR_000228
KBioGR_000439
KBioSS_000228
KBioSS_001797
LS-36330
Leo Brand of Bumetanide
Lixil
Lixil-Leo
Lopac-B-3023
Lopac0_000162
Lunetoron
MLS000028457
MLS001148265
Miccil
MolPort-003-666-390
NCGC00015149-01
NCGC00015149-02
NCGC00015149-03
NCGC00015149-06
NCGC00015149-12
NCGC00022072-03
NCGC00022072-04
NCGC00022072-05
NCGC00022072-06
NCGC00022072-07
NCGC00022072-08
NINDS_000034
PF 1593
PF-1593
PF1593
Prestwick0_000276
Prestwick1_000276
Prestwick2_000276
Prestwick3_000276
Prestwick_679
Ro 10-6338
Ro-10-6338
Roche Brand of Bumetanide
S1287_Selleck
SAM002564195
SMP1_000049
SMR000058418
SPBio_000980
SPBio_002371
SPECTRUM1502004
ST51014910
Segurex
Senosiain Brand of Bumetanide
Spectrum2_001050
Spectrum3_001481
Spectrum4_000030
Spectrum5_001212
Spectrum_001317
UNII-0Y2S3XUQ5H
Yurinex
bumetanide
14diureticsPhase 21194
15Sodium Potassium Chloride Symporter InhibitorsPhase 2130
16Natriuretic AgentsPhase 21403
17Contraceptives, OralPhase 13734
18Immunoglobulins4477
19Antibodies4477

Interventional clinical trials:

idNameStatusNCT IDPhase
1Hyper- and Hypokalemic Periodic Paralysis StudyCompletedNCT00494507Phase 3
2Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel DisordersCompletedNCT00004802Phase 3
3Lamotrigine as Treatment of MyotoniaCompletedNCT01939561Phase 3
4Bumetanide in Hypokalaemic Periodic ParalysisRecruitingNCT02582476Phase 2
5Use of Minocicline in Patients With StrokeRecruitingNCT01556802Phase 1
6Genetic Analysis of Thyrotoxic Periodic ParalysisCompletedNCT00443833
7Characteristics of Andersen-Tawil SyndromeCompletedNCT00521794
8Genetic and Morphological Analysis of Thyrotoxic Periodic ParalysisActive, not recruitingNCT02287363

Search NIH Clinical Center for Periodic Paralyses

Genetic Tests for Periodic Paralyses

About this section

Anatomical Context for Periodic Paralyses

About this section

MalaCards organs/tissues related to Periodic Paralyses:

33
T cells, Thyroid, Breast, Liver, Temporal lobe, Tongue, Neutrophil

Animal Models for Periodic Paralyses or affiliated genes

About this section

MGI Mouse Phenotypes related to Periodic Paralyses:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053889.1KCNE3, KCNJ2, SCN4A
2MP:00053818.8CACNA1S, KCNE3, KCNJ2
3MP:00053698.6CACNA1S, KCNJ2, SCN4A

Publications for Periodic Paralyses

About this section

Articles related to Periodic Paralyses:

(show all 33)
idTitleAuthorsYear
1
Clinical and immunological features and outcome of anti-p200 pemphigoid. (27037896)
2016
2
Dopamine Burden Triggers Neurodegeneration via Production and Release of TNF-I+ from Astrocytes in Minimal Hepatic Encephalopathy. (26433377)
2015
3
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. (23182985)
2013
4
Somatosensory processing and borderline personality disorder features: a signal detection analysis of proprioception and exteroceptive sensitivity. (23514184)
2013
5
Hippocampal gene expression dysregulation of Klotho, nuclear factor kappa B and tumor necrosis factor in temporal lobe epilepsy patients. (23634661)
2013
6
An unusual case of giant cell myocarditis missed in a Heartmate-2 left ventricle apical-wedge section: a case report and review of the literature. (23324434)
2013
7
Angiosarcoma arising from the tongue of an 11-year-old girl with xeroderma pigmentosum. (21987224)
2012
8
The diverse functions of GAPDH: views from different subcellular compartments. (20727968)
2011
9
Physical properties of root cementum: part 21. Extent of root resorption after the application of 2.5A^ and 15A^ tips for 4 weeks: a microcomputed tomography study. (22133964)
2011
10
T-type current modulation by the actin-binding protein Kelch-like 1. (20147652)
2010
11
Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. (18593762)
2008
12
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. (18676832)
2008
13
Optical coherence tomography characteristics of full-thickness traumatic macular holes. (17828143)
2008
14
Staphylococcal pericarditis, and liver and paratracheal abscesses as presentations in two new cases of interleukin-1 receptor associated kinase 4 deficiency. (18174872)
2008
15
Loss of E-cadherin-mediated cell contacts reduces estrogen receptor alpha (ER alpha) transcriptional efficiency by affecting the respective contribution exerted by AF1 and AF2 transactivation functions. (17991426)
2008
16
Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells. (17121800)
2007
17
Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway. (15856031)
2005
18
PLAG1-HAS2 fusion in lipoblastoma with masked 8q intrachromosomal rearrangement. (15642402)
2005
19
Omental transfer for mediastinitis in a patient with early gastric cancer. (15510842)
2004
20
Role of color Doppler imaging in diagnosing and managing pregnancies complicated by placental chorioangioma. (12116105)
2002
21
Endolymphatic hydrops in asymptomatic ears in unilateral MAcniA"re's disease. (11359166)
2001
22
Drug therapy of hyperlipidemia. Current status in Germany]. (11820153)
2001
23
Effect of hormone balance on carbohydrate-deficient transferrin and gamma-glutamyltransferase in female social drinkers. (11045858)
2000
24
H2-E transgenic class II-negative mice can distinguish self from nonself in susceptibility to heterologous thyroglobulins in autoimmune thyroiditis. (10541803)
1999
25
Structure of human G protein Ggamma5 gene GNG5. (9790912)
1998
26
Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta. (8707349)
1996
27
Corticosteroids and medroxyprogesterone acetate inhibit the induction of E-selectin on the vascular endothelium by MDA-MB-231 breast cancer cells. (8669817)
1995
28
Congenital erythropoietic porphyria: identification and expression of 10 mutations in the uroporphyrinogen III synthase gene. (7860775)
1995
29
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. (8635066)
1995
30
The role of vertebral and internal carotid artery disease in the pathogenesis of vertebrobasilar transient ischemic attacks. (8461343)
1993
31
Enzymatic iodination of thyroglobulins obtained from patients with thyroid disease]. (1752339)
1991
32
Endoscopic treatment of ureterocele and antireflux injection with Teflon paste. (2364974)
1990
33
Long-term antibiotic therapy in tropical sprue. (5838328)
1965

Variations for Periodic Paralyses

About this section

Expression for genes affiliated with Periodic Paralyses

About this section
Search GEO for disease gene expression data for Periodic Paralyses.

GO Terms for genes affiliated with Periodic Paralyses

About this section

Biological processes related to Periodic Paralyses according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1muscle contractionGO:00069369.0CACNA1S, SCN4A

Sources for Periodic Paralyses

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet